213 related articles for article (PubMed ID: 34982509)
1. Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection.
Kim HK; Cho J; Kim E; Kim J; Yang JS; Kim KC; Lee JY; Shin Y; Palomera LF; Park J; Baek SH; Bae HG; Cho Y; Han J; Sul JH; Lee J; Park JH; Cho YW; Lee W; Jo DG
J Extracell Vesicles; 2022 Jan; 11(1):e12179. PubMed ID: 34982509
[TBL] [Abstract][Full Text] [Related]
2. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.
El-Shennawy L; Hoffmann AD; Dashzeveg NK; McAndrews KM; Mehl PJ; Cornish D; Yu Z; Tokars VL; Nicolaescu V; Tomatsidou A; Mao C; Felicelli CJ; Tsai CF; Ostiguin C; Jia Y; Li L; Furlong K; Wysocki J; Luo X; Ruivo CF; Batlle D; Hope TJ; Shen Y; Chae YK; Zhang H; LeBleu VS; Shi T; Swaminathan S; Luo Y; Missiakas D; Randall GC; Demonbreun AR; Ison MG; Kalluri R; Fang D; Liu H
Nat Commun; 2022 Jan; 13(1):405. PubMed ID: 35058437
[TBL] [Abstract][Full Text] [Related]
3. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
4. GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
Tsai MS; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
Biomed Pharmacother; 2021 Oct; 142():112011. PubMed ID: 34388530
[TBL] [Abstract][Full Text] [Related]
5. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
6. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
Yeung ML; Teng JLL; Jia L; Zhang C; Huang C; Cai JP; Zhou R; Chan KH; Zhao H; Zhu L; Siu KL; Fung SY; Yung S; Chan TM; To KK; Chan JF; Cai Z; Lau SKP; Chen Z; Jin DY; Woo PCY; Yuen KY
Cell; 2021 Apr; 184(8):2212-2228.e12. PubMed ID: 33713620
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
[TBL] [Abstract][Full Text] [Related]
8. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection.
Feng F; Chen J; Zhao J; Li Y; Li M; Sun C
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835049
[TBL] [Abstract][Full Text] [Related]
9. Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles.
Lim K; Nishide G; Yoshida T; Watanabe-Nakayama T; Kobayashi A; Hazawa M; Hanayama R; Ando T; Wong RW
J Extracell Vesicles; 2021 Dec; 10(14):e12170. PubMed ID: 34874124
[TBL] [Abstract][Full Text] [Related]
10. Investigation on the interaction mechanism of different SARS-CoV-2 spike variants with hACE2: insights from molecular dynamics simulations.
Wu J; Zhang HX; Zhang J
Phys Chem Chem Phys; 2023 Jan; 25(3):2304-2319. PubMed ID: 36597957
[TBL] [Abstract][Full Text] [Related]
11. Soluble ACE2 as a potential therapy for COVID-19.
Krishnamurthy S; Lockey RF; Kolliputi N
Am J Physiol Cell Physiol; 2021 Mar; 320(3):C279-C281. PubMed ID: 33502950
[TBL] [Abstract][Full Text] [Related]
12. Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients.
Rahman MM; Hasan M; Ahmed A
Rev Med Virol; 2021 Sep; 31(5):1-12. PubMed ID: 33426683
[TBL] [Abstract][Full Text] [Related]
13. Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity.
Gong SY; Chatterjee D; Richard J; Prévost J; Tauzin A; Gasser R; Bo Y; Vézina D; Goyette G; Gendron-Lepage G; Medjahed H; Roger M; Côté M; Finzi A
Virology; 2021 Nov; 563():134-145. PubMed ID: 34536797
[TBL] [Abstract][Full Text] [Related]
14. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
[TBL] [Abstract][Full Text] [Related]
15. Proviral role of human respiratory epithelial cell-derived small extracellular vesicles in SARS-CoV-2 infection.
Berry F; Morin-Dewaele M; Majidipur A; Jamet T; Bartier S; Ignjatovic E; Toniutti D; Gaspar Lopes J; Soyeux-Porte P; Maillé P; Saldana C; Brillet R; Ahnou N; Softic L; Couturaud B; Huet É; Ahmed-Belkacem A; Fourati S; Louis B; Coste A; Béquignon É; de la Taille A; Destouches D; Vacherot F; Pawlotsky JM; Firlej V; Bruscella P
J Extracell Vesicles; 2022 Oct; 11(10):e12269. PubMed ID: 36271885
[TBL] [Abstract][Full Text] [Related]
16. Potential inhibitor for blocking binding between ACE2 and SARS-CoV-2 spike protein with mutations.
Tsai MS; Shih WT; Yang YH; Lin YS; Chang GH; Hsu CM; Yeh RA; Shu LH; Cheng YC; Liu HT; Wu YH; Wu YH; Shen RC; Wu CY
Biomed Pharmacother; 2022 May; 149():112802. PubMed ID: 35279013
[TBL] [Abstract][Full Text] [Related]
17. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
[TBL] [Abstract][Full Text] [Related]
18. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
19. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
[TBL] [Abstract][Full Text] [Related]
20. Differential Interactions between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
Kim S; Liu Y; Lei Z; Dicker J; Cao Y; Zhang XF; Im W
J Chem Theory Comput; 2021 Dec; 17(12):7972-7979. PubMed ID: 34856802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
